No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Gregg M. Gellman Appointed CEO of Open Implants: Offers Deep Medical Device Development & Manufacturing Business Development Experience

Editor: What To Know

  • “My roots are in orthopedics, regulated manufacturing and advanced technologies and I look forward to working with customers and the Open Implants team to accelerate product development and increase our commitments to insure customer satisfaction and above all positive clinical outcomes for patients who require dental surgery.
  •  Rapp will continue as a member of the Board of Directors and will also continue full-time leadership of his dental laboratory, CrownCeram, in France.
  • Gellman’s previous experience includes executive leadership roles at EBI Biomet, now Zimmer Biomet, Greatbatch now Integer Holdings, EnerMed now Garwood Medical, StimMed and Thinking Robot Studios where he will continue to serve as a Board Member for both companies.

Gregg M. Gellman has more than 15 years of experience, leading and growing biomedical companies. He brings a unique and strong skill set to the company.

Gellman’s previous experience includes executive leadership roles at EBI Biomet, now Zimmer Biomet, Greatbatch now Integer Holdings, EnerMed now Garwood Medical, StimMed and Thinking Robot Studios where he will continue to serve as a Board Member for both companies. He has a proven track record in product development, commercialization of regulated applications/products, regulatory and sales. Gellman is a graduate of the State University of New York at Buffalo. He is certified in Quality Systems for Medical Devices (FDA’s QSR and ISO 13485) and in Global Product Submissions Directive Requirements (510(k), PMA, CE Mark).

Greg M. Gellman feels this is a tremendous opportunity to contribute to building on what Open Implants has already accomplished. “My roots are in orthopedics, regulated manufacturing and advanced technologies and I look forward to working with customers and the Open Implants team to accelerate product development and increase our commitments to insure customer satisfaction and above all positive clinical outcomes for patients who require dental surgery.”

Rob Nazzal, Co-founder and Board Member, says, “Gregg’s deep experience in medical device development, manufacturing, and business development, will be an enormous asset for Open Implants. With Gregg onboard, we are accelerating our roadmap to deliver more comprehensive solutions to the evolving digital dentistry world. We are privileged to have Gregg on our team.”

Gregg M. Gellmen succeeds Frederic Rapp, who is also a co-founder of Open Implants. Rapp will continue as a member of the Board of Directors and will also continue full-time leadership of his dental laboratory, CrownCeram, in France.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy